2024/08/16 18:12:32 | |
---|---|
Price | |
16.00 USD | |
Difference | 6.67% (1.00) |
ISIN | CH0325814116 |
Symbol | KURN |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 559 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 15.67 USD |
High | 16.03 USD |
Low | 15.67 USD |
Close (prev. day) | 15.00 USD |
VWAP | 15.952381 USD |
Volume (pcs) | 6,300 |
Trading volume | 100,500.00 |
Number of trades | 3 |
Last size | 4,300 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/08/12 |
![]() |
Global Equity Ratings |
![]() |
2024/07/24 |
![]() |
Global Equity Ratings |
![]() |
2024/07/12 |
![]() |
Global Equity Ratings |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/08/16 18:12:32 | |
---|---|
Price | |
16.00 USD | |
Difference | 6.67% (1.00) |
ISIN | CH0325814116 |
Symbol | KURN |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 559 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 15.67 USD |
High | 16.03 USD |
Low | 15.67 USD |
Close (prev. day) | 15.00 USD |
VWAP | 15.952381 USD |
Volume (pcs) | 6,300 |
Trading volume | 100,500.00 |
Number of trades | 3 |
Last size | 4,300 |
6m | 1Y | 3Y | |
Perf (%) | +135.29% | - | +433.33% |
Perf (abs.) | +9.20 | - | +13.00 |
Beta | 0.90 | 0.94 | 0.62 |
Volatility | 130.19 | 130.88 | 123.28 |
Ø price 5 days | Ø volume 5 days (pcs.) | 14.53 USD (1,360) |
Ø price 30 days | Ø volume 30 days (pcs.) | 14.08 USD (669) |
Ø price 100 days | Ø volume 100 days (pcs.) | 10.26 USD (1,236) |
Ø price 250 days | Ø volume 250 days (pcs.) | 7.94 USD (1,009) |
YTD High | date | 16.03 USD (2024/08/16) |
YTD Low | date | 4.40 USD (2024/01/03) |
52 Weeks High | date | 16.03 USD (2024/08/16) |
52 Weeks Low | date | 2.13 USD (2023/09/07) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
SIX Swiss Exchange | 2024/08/16 | 17:31 | 14.36 CHF | 9.51 | 1,759 |
London Stock Exchange | 2022/12/16 | 17:52 | 1.505 CHF | 0.05 | 1 |
Frankfurt | 2019/06/28 | 09:05 | 1.4054 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/08/16 | 18:12 | 16.00 USD | 0.10 | 3 |
KUROS BIOSCIENCES LTD. |
- - |
Wagistrasse 25 - 8952 Schlieren |
Telefon: +41-44-733-47-47 |
Fax: +41-44-733-47-40 |
E-mail: info@kuros.ch |
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland. |
Chris Fair | Chairman of Managing Board |
Philippe Saudan | Member of Executive Committee |
Joost de Bruijn | Member of Executive Committee |
Daniel Geiger | Member of Executive Committee |
John Griffin | Member of Executive Committee |
Sjoerd Musters | Member of Executive Committee |
Joost de Bruijn | Member of the administrative board |
Albert Arp | Member of the administrative board |
Oliver Walker | Member of the administrative board |
Clemens van Blitterswijk | Chairman of the administrative boar |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer